J Med Microbiol Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Valéria dos Santos, K.
Right arrow Articles by Roque de Carvalho, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Valéria dos Santos, K.
Right arrow Articles by Roque de Carvalho, M. A.
Agricola
Right arrow Articles by Valéria dos Santos, K.
Right arrow Articles by Roque de Carvalho, M. A.
J Med Microbiol 56 (2007), 798-802; DOI: 10.1099/jmm.0.47112-0
© 2007 Society for General Microbiology
ISSN 1473-5644

In vitro activity of piperacillin/tazobactam and ertapenem against Bacteroides fragilis and Escherichia coli in pure and mixed cultures

Kênia Valéria dos Santos, Cláudio Galuppo Diniz, Simone Cristina Coutinho, Ana Carolina Morais Apolônio, Luciana Geralda de Sousa-Gaia, Jacques Robert Nicoli, Luiz de Macêdo Farias and Maria Auxiliadora Roque de Carvalho

Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil

Correspondence
Maria Auxiliadora Roque de Carvalho
marc{at}icb.ufmg.br

Received 7 December 2006
Accepted 18 February 2007

Ertapenem and piperacillin/tazobactam are ß-lactam antibiotics with a broad spectrum of activity used for the treatment of mixed infections in which Bacteroides fragilis and Escherichia coli play an important aetiological role. In this study, the activities of piperacillin/tazobactam and ertapenem (MIC and time–kill kinetics) against these bacteria were compared. MICs were determined by the agar dilution method, and the time and slope of time–kill curves were analysed. In the in vitro pharmacodynamic assays, pure and mixed cultures of E. coli and B. fragilis were exposed to peak concentrations of ertapenem (8.0 µg ml–1) and piperacillin/tazobactam (64.0/8.0 µg ml–1) for 48 h. Treatment with ertapenem reduced the viability of E. coli and/or B. fragilis by 3 logs in all experiments, whereas piperacillin/tazobactam only affected the viability of B. fragilis. Both drugs exhibited their fastest rates of killing when bacteria were grown in mixed cultures. According to the results, ertapenem exhibited activity similar to that of piperacillin/tazobactam against B. fragilis alone or in mixed culture. However, ertapenem exhibited a markedly higher activity against E. coli alone or in combination with B. fragilis relative to piperacillin/tazobactam.

Abbreviations: LLA, lower limit of accuracy.




This article has been cited by other articles:


Home page
 J Med MicrobiolHome page
K. V. d. Santos, J. R. Nicoli, W. A. Martins, S. C. Coutinho, A. C. M. Apolonio, C. G. Diniz, M. A. R. d. Carvalho, and L. d. M. Farias
Comparative activity of ertapenem and piperacillin tazobactam in a murine systemic infection model with Bacteroides fragilis and Escherichia coli
J. Med. Microbiol., November 1, 2007; 56(11): 1576 - 1579.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
INT J SYST EVOL MICROBIOL J MED MICROBIOL MICROBIOLOGY J GEN VIROL ALL SGM JOURNALS
Copyright © 2007 Society for General Microbiology.